Four Pharmaceutical stocks are moving up in their overall rating this week, according to the Portfolio Grader database. Every one of these is graded an “A” (“strong buy”) or “B” overall (“buy”).
This week, Johnson & Johnson (NYSE:JNJ) is showing good progress as the company’s rating jumps from a B (“buy”) last week to an A (“strong buy”). Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. In Portfolio Grader’s specific subcategories of Earnings Growth, Earnings Momentum, and Equity, JNJ also gets A’s. The current dividend yield is 2.6%. For more information, get Portfolio Grader’s complete analysis of JNJ stock.
This week, Bristol-Myers Squibb Company (NYSE:BMY) is showing significant improvement as the company’s rating hops from a C (“hold”) to a B (“buy”). Bristol-Myers Squibb is a global company that develops, produces and sells pharmaceutical products. For more information, get Portfolio Grader’s complete analysis of BMY stock.
Watson Pharmaceuticals (NYSE:WPI) shows solid improvement this week. The company’s rating rises from a B to an A. Watson develops, manufactures, markets, sells and distributes pharmaceutical products. For more information, get Portfolio Grader’s complete analysis of WPI stock.
Repros Therapeutics (NASDAQ:RPRX) improves from a B to an A rating this week. Repros Therapeutics is a development stage biopharmaceutical company focusing on the development of oral small molecule drugs for major unmet medical needs. The stock price has risen 17.6% over the past month, better than the 1.3% decrease the Nasdaq has seen over the same period of time. For more information, get Portfolio Grader’s complete analysis of RPRX stock.
Louis Navellier’s proprietary Portfolio Grader stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results — with A being “strong buy,” and F being “strong sell.” Explore the tool here.